Table 3.

Estimated Regression Coefficient and SEs of Biomarker Concentrations based on a Mixed-Effects Model with Time Points (days) Defined at Initial Cycle (Days 0, 3 and 10), and Subsequent Cycle (Days 0, 3 and 10)^a.

Biomarkersb	Group	Days	Time point vs. Baseline (Days)	Estimated Regression Coefficientsc	SE	P value
KIM-1	Initial	0	Intercept	1.14	0.47	0.0232
		3	3 vs. baseline	1.08	0.54	0.0489
		10	10 vs. baseline	1.02	0.54	0.0579
	Subsequent	0	36 vs. baseline	1.21	0.54	0.0261
		3	39 vs. baseline	1.72	0.54	0.0017
		10	46 vs. baseline	1.05	0.54	0.0543
Calbindin	Initial	0	Intercept	6.64	5.77	0.2608
		3	3 vs. baseline	−1.38	7.51	0.8540
		10	10 vs. baseline	29.40	7.51	0.0001
	Subsequent	0	36 vs. baseline	2.32	7.50	0.7578
		3	39 vs. baseline	3.45	7.43	0.6433
		10	46 vs. baseline	11.93	7.51	0.1146
TFF3	Initial	0	Intercept	21.42	10.26	0.0467
		3	3 vs. baseline	23.07	9.79	0.0200
		10	10 vs. baseline	11.00	9.68	0.2581
	Subsequent	0	36 vs. baseline	2.58	9.76	0.7915
		3	39 vs. baseline	29.66	9.68	0.0027
		10	46 vs. baseline	27.00	9.79	0.0067

^aAbbreviations: KIM-1: kidney injury molecule 1, TFF3: trefoil factor 3.

^bBiomarker concentrations were normalized to urinary creatinine levels.

^cEstimated regression coefficients and standard errors (SE) were obtained using a Mixed-Effects Model with time as a categorical covariate variable and intercept as a random effect. Initial Day 0 is referenced as baseline.